Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Regeneron Pharmaceuticals (NasdaqGS:REGN) was removed from multiple key indices, a development that may influence its investment appeal and stock liquidity. Over the last month, the company's shares ...

REGN is one of the 7 52-week low dividend stocks to consider Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biotechnology company, develops treatments in ophthalmology, oncology, and immunology.

Review the current Regeneron Pharmaceuticals Inc (REGN:XNAS) dividend yield and history to decide if REGN is the best investment for you.

The cuts represent less than 4% of the company's global workforce and come on top of about 6,000 roles it eliminated in May. Global vehicle sales fall 13.5% as the electric- vehicle maker struggles to ...

Argus downgraded Regeneron Pharmaceuticals from a buy to a hold rating in its latest research report, signaling caution.

Bessemer Group significantly trimmed its investment in Regeneron Pharmaceuticals during the first quarter, slashing its stake ...